Cara Therapeutics, Inc. (NASDAQ:CARA) Given Consensus Recommendation of “Hold” by Analysts

Cara Therapeutics, Inc. (NASDAQ:CARAGet Free Report) has been assigned an average rating of “Hold” from the six research firms that are presently covering the stock, MarketBeat reports. Six equities research analysts have rated the stock with a hold rating. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $3.93.

A number of research analysts recently issued reports on the company. Canaccord Genuity Group lowered Cara Therapeutics from a “buy” rating to a “hold” rating and reduced their price objective for the company from $10.00 to $1.00 in a research report on Thursday, June 13th. Stifel Nicolaus lowered Cara Therapeutics from a “buy” rating to a “hold” rating and reduced their price objective for the company from $6.00 to $1.00 in a research report on Thursday, June 13th. Needham & Company LLC lowered Cara Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, June 13th. StockNews.com initiated coverage on Cara Therapeutics in a research report on Monday. They set a “sell” rating for the company. Finally, HC Wainwright lowered Cara Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, June 13th.

Get Our Latest Analysis on Cara Therapeutics

Cara Therapeutics Stock Up 4.7 %

CARA stock opened at $0.28 on Monday. Cara Therapeutics has a 52-week low of $0.24 and a 52-week high of $3.45. The stock’s 50 day moving average is $0.57 and its two-hundred day moving average is $0.67. The company has a market capitalization of $15.57 million, a PE ratio of -0.13 and a beta of 0.69.

Cara Therapeutics (NASDAQ:CARAGet Free Report) last issued its quarterly earnings results on Monday, May 13th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.18). Cara Therapeutics had a negative net margin of 723.49% and a negative return on equity of 174.15%. The firm had revenue of $2.14 million during the quarter, compared to the consensus estimate of $2.25 million. As a group, sell-side analysts anticipate that Cara Therapeutics will post -1.28 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of CARA. Mackenzie Financial Corp grew its stake in Cara Therapeutics by 71.2% in the fourth quarter. Mackenzie Financial Corp now owns 53,678 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 22,329 shares in the last quarter. Marquette Asset Management LLC purchased a new position in Cara Therapeutics in the first quarter valued at about $86,000. Assenagon Asset Management S.A. boosted its stake in shares of Cara Therapeutics by 155.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 167,838 shares of the biopharmaceutical company’s stock worth $125,000 after acquiring an additional 102,230 shares in the last quarter. Federated Hermes Inc. boosted its stake in shares of Cara Therapeutics by 3.5% during the 4th quarter. Federated Hermes Inc. now owns 831,849 shares of the biopharmaceutical company’s stock worth $618,000 after acquiring an additional 28,365 shares in the last quarter. Finally, Rosalind Advisors Inc. bought a new stake in shares of Cara Therapeutics during the 1st quarter worth about $1,409,000. Hedge funds and other institutional investors own 44.66% of the company’s stock.

Cara Therapeutics Company Profile

(Get Free Report

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.

Featured Stories

Analyst Recommendations for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.